| Target Molecule | Thymalfasin |
| Synonyms | Thymosin alpha-1, Tα1, Zadaxin |
| CAS Number | 69440-99-9 (thymalfasin); thymosin alpha-1 also listed as 62304-98-7 |
| Sequence (3-Letter) | Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH |
| Sequence (1-Letter) | Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN |
| Molecular Formula | C₁₂₉H₂₁₅N₃₃O₅₅ |
| Molecular Weight | 3108.3 |
| Service Category | Custom Peptide Synthesis / CDMO Manufacturing |
| Synthesis Purity | Customizable (e.g., ≥95%, ≥98% via HPLC) |
| Appearance | White to off-white lyophilized powder |
| Counter Ion | Acetate (standard pharmaceutical salt), TFA, or custom salt options |
| Synthesis Technology | Solid-Phase Peptide Synthesis (SPPS) with Precision N-Terminal Capping |
| Modification Options | N-terminal acetylation, stable isotope labeling (13C, 15N), fluorescent tags, deamidation standards |
| Available Scale | Milligram (R&D) to Kilogram (Commercial CDMO) |
| Analytical Data | Comprehensive COA, HPLC, MS, and capping confirmation provided per batch |
| Usage | Raw material synthesized strictly for laboratory research, analytical development, and industrial formulation. Not a finished medicine. |
Thymalfasin (CAS 69440-99-9), the synthetic pharmaceutical name for thymosin alpha-1, is a 28-amino-acid immunomodulatory peptide featuring N-terminal acetylation (Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN). We target this sequence to supply high-purity reference materials, analytical standards, and raw materials for immunology, oncology, and infectious disease research.
Assembling a 28-residue sequence containing multiple aspartic acid and glutamic acid residues introduces significant risks of aspartimide formation and chain aggregation. Our peptide synthesis platform utilizes low-loading resins, optimized coupling reagents, and continuous monitoring, coupled with quantitative capping chemistry to ensure complete N-terminal acetylation and eliminate deletion impurities.
Yes. We provide specialized peptide modification services for Thymalfasin. Capabilities include site-specific stable isotope labeling (13C, 15N) for quantitative mass spectrometry (LC-MS/MS), fluorescent and biotin tagging, and the synthesis of unacetylated, deamidated, or beta-aspartyl reference standards for stability-indicating analytical assays.
Our manufacturing infrastructure scales production from milligram-level analytical batches to multigram and kilogram commercial quantities. We optimize preparative HPLC purification and controlled counter-ion exchange (ensuring acetate salt conversion) to guarantee strict batch-to-batch consistency.
We operate as an integrated technical partner providing complete peptide CDMO solutions. Our team manages sequence optimization, impurity profiling, analytical method validation, and regulatory documentation to accelerate complex preclinical and commercial pipelines.
Thymalfasin (CAS 69440-99-9), marketed under trade names including Zadaxin, is a synthetic 28-amino-acid peptide defined by the N-terminally acetylated sequence Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN. Identical in chemical sequence to thymosin alpha-1, it functions as an essential regulator of immune response by promoting T-cell differentiation and maturation. Synpeptide delivers comprehensive custom synthesis solutions for this molecule, demonstrating advanced technical expertise in long-chain assembly, capping chemistries, and CDMO manufacturing.
Constructing a 28-amino acid sequence with consecutive acidic residues (Asp, Glu) presents notable chemical hurdles during solid-phase elongation, particularly the formation of aspartimide intermediates. Our custom peptide synthesis platform resolves these hurdles using optimized Solid-Phase Peptide Synthesis (SPPS) protocols on low-loading resins. By implementing base-protecting cocktails, temperature control, and complete N-terminal acetyl capping, we suppress deletion fragments and epimerization, delivering raw materials with rigorous purity specifications (typically ≥95% or ≥98% via HPLC).
The native stability and biological activity of Thymalfasin rely strictly on complete N-terminal acetylation. Incomplete capping leaves unacetylated peptide, which represents a critical process-related impurity. Through our peptide modification services, we execute precise capping protocols and synthesize defined unacetylated, deamidated, or beta-aspartyl variants to serve as reference standards for stability-indicating assays. We also provide stable isotope labeling (13C, 15N) and fluorescent conjugates for pharmacokinetic bioanalysis.
Transitioning an immunomodulatory peptide from analytical scale to commercial volume demands robust chemical engineering during downstream processing. We execute large-scale peptide synthesis for Thymalfasin by optimizing fluid dynamics and high-capacity preparative HPLC purification. Our facilities accommodate requirements from milligram research batches to kilogram commercial lots, ensuring uniform counter-ion exchange (consistently achieving the pharmaceutical acetate salt form) across all production volumes.
We deliver comprehensive technical support as a fully established peptide CDMO. Our development specialists assist pharmaceutical partners with process optimization, stability testing, impurity identification, and analytical method validation. Every batch is released with complete documentation—including COA, HPLC purity traces, and exact mass confirmation—ensuring regulatory alignment for downstream therapeutic programs.
